There is no guaranteed cure for ovarian cancer, but some patients do achieve long-term remission and never see the disease return. The likelihood depends heavily on when it’s caught and how completely it can be treated. When ovarian cancer is found while still confined to the ovary, the five-year survival rate is nearly 92%. The challenge is that most cases aren’t caught that early, and advanced-stage disease recurs in roughly 70% of patients within five years.
What “Cure” Actually Means in Ovarian Cancer
Oncologists rarely use the word “cure” with ovarian cancer. Instead, they talk about remission or “no evidence of disease,” both of which mean that no cancer is currently detectable through scans, bloodwork, or biopsies. Being declared “cancer-free” is a stronger claim: it implies no residual cancer exists anywhere in the body and the disease won’t come back. That’s a difficult promise to make because there is always at least a slight risk of recurrence for anyone who has had cancer.
There’s no formal medical milestone, like a five-year or ten-year mark, that officially converts remission into a cure. But doctors sometimes begin using the term “cancer-free” after enough time has passed without relapse, typically when a patient transitions from active monitoring to less frequent check-ups. For practical purposes, a person who reaches that point is living as though the cancer is behind them, even if the medical language stays cautious.
Why Stage at Diagnosis Changes Everything
The most recent data from the National Cancer Institute’s SEER program shows striking differences in five-year survival based on how far the cancer has spread at the time of diagnosis:
- Localized (still in the ovary): 91.9%
- Regional (spread to nearby lymph nodes or tissue): 70.1%
- Distant (spread to other organs): 31.5%
Those numbers reflect relative survival, meaning they compare ovarian cancer patients to the general population of the same age. A localized diagnosis puts a patient in a strong position, but ovarian cancer is notoriously difficult to detect early. It often produces vague symptoms like bloating, pelvic pressure, or feeling full quickly, which are easy to attribute to other causes. By the time most patients are diagnosed, the cancer has already spread beyond the ovary.
How Treatment Works
The standard approach for advanced ovarian cancer has two core components: surgery to remove as much visible tumor as possible, followed by platinum-based chemotherapy (often combined with a second drug). This framework has been the backbone of treatment for over 25 years, though important additions have been made in recent years.
The surgery, called cytoreductive or debulking surgery, has an outsized impact on outcomes. Data from patients with stage IV disease illustrates this clearly. Those whose surgeons removed all visible tumor had a median overall survival of 50 months. When even small amounts of residual tumor remained (1 to 10 millimeters), that dropped to 25 months. Patients with more than 10 millimeters of remaining disease survived a median of 16 months. The gap between complete and incomplete removal is one of the biggest single factors in ovarian cancer prognosis, which is why getting care at a high-volume cancer center with experienced gynecologic oncologists matters.
Maintenance Therapy After Chemotherapy
One of the most significant advances in ovarian cancer treatment is the use of maintenance therapy, drugs taken after initial chemotherapy to delay or prevent recurrence. The most prominent class is PARP inhibitors, which work by blocking a DNA repair mechanism that cancer cells rely on. These drugs have shown the strongest benefit in patients whose tumors carry BRCA gene mutations or similar DNA repair deficiencies.
In one major trial, a PARP inhibitor extended median overall survival by nearly 13 months compared to placebo in patients with recurrent disease who had responded to platinum chemotherapy. Another option is bevacizumab, a drug that starves tumors by blocking new blood vessel growth, used alongside chemotherapy and then continued as maintenance. The choice between these options depends on the timing and results of surgery, how well a patient responds to chemotherapy, and the tumor’s genetic profile.
The Role of Genetic Testing
About 15 to 20% of ovarian cancer patients carry inherited mutations in the BRCA1 or BRCA2 genes. These mutations, somewhat counterintuitively, are associated with better initial treatment response. Tumors with BRCA mutations are more sensitive to platinum chemotherapy and respond particularly well to PARP inhibitors. A meta-analysis of over 4,500 patients found that BRCA mutation carriers had a five-year survival rate roughly 15 percentage points higher than non-carriers.
That advantage narrows over time, though. At ten years, the difference shrank to about 9 percentage points, and among patients who had already survived five years, carrying a BRCA mutation provided no additional survival benefit going forward. The early sensitivity to treatment gives BRCA carriers a meaningful head start, but it doesn’t guarantee long-term freedom from the disease. Genetic testing is now standard for all ovarian cancer patients because it directly shapes which treatments are most likely to work.
Newer Treatment Options
For patients whose cancer has stopped responding to platinum chemotherapy (called platinum-resistant disease), options have historically been limited. A newer drug called mirvetuximab soravtansine targets a protein found on the surface of many ovarian cancer cells. It works as an antibody-drug conjugate, essentially a guided missile that delivers chemotherapy directly to cells displaying this protein.
In clinical trials, mirvetuximab improved median overall survival to about 16.5 months compared to 12.75 months with standard chemotherapy in patients with platinum-resistant disease whose tumors expressed high levels of the target protein. The response rate was 42% versus 16% with conventional treatment. Not every patient’s tumor expresses the protein at high enough levels to qualify, so testing is required. This drug represents a meaningful new option for a group of patients who previously had few effective choices.
Living With Recurrence
The 70% recurrence rate in advanced ovarian cancer is the central challenge. When cancer comes back, it can often be treated again, sometimes with the same platinum-based chemotherapy if enough time has passed since the last treatment. Each subsequent recurrence, however, tends to respond less well and for a shorter duration. This is why the initial treatment, and particularly maintenance therapy, is so critical. Extending the time before a first recurrence gives patients not just more time but often better quality of life during that period.
For the subset of patients whose cancer does not return after initial treatment, the practical reality is indistinguishable from a cure. They complete their therapy, transition to periodic monitoring, and eventually see their appointments spaced further and further apart. The medical system may never use the word “cure,” but for those patients, the cancer is over. The honest answer is that this outcome is achievable for some patients, more likely in early-stage disease, and that treatment advances are steadily expanding who those patients are.